Showing results (111-120 of 734) with videos related to
Sort By:
Pageof 74
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2012
Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximabSabine Tejpar, Ilhan Celik, Michael Schlichting, et al.Journal of the American Society of Nephrology : JASN|December 14, 2004
Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, single-blinded, placebo-controlled trialPeter Benoehr, Patricia Krueth, Carsten Bokemeyer, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 31, 2013
Multimodal exercise training during myeloablative chemotherapy: a prospective randomized pilot trialKarin Oechsle, Zeynep Aslan, Yvonne Suesse, et al.Frontiers in Oncology|March 31, 2023
NTRK fusion protein expression is absent in a large cohort of diffuse large B-cell lymphomaSusanne Ghandili, Judith Dierlamm, Carsten Bokemeyer, et al.Journal of Clinical Medicine|November 25, 2023
Further Association of Germline CHEK2 Loss-of-Function Variants with Testicular Germ Cell TumorsKira Kirchner, Christoph Seidel, Finn-Ole Paulsen, et al.International Journal of Molecular Sciences|December 23, 2018
5-Azacitidine Exerts Prolonged Pro-Apoptotic Effects and Overcomes Cisplatin-Resistance in Non-Seminomatous Germ Cell Tumor CellsChristoph Oing, Izudin Verem, Wael Y Mansour, et al.Anticancer Research|August 19, 2007
A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancerChristof Burkart, Carsten Bokemeyer, Bodo Klump, et al.Cancer Chemotherapy and Pharmacology|December 8, 2010
Evaluation of a non cystatin-C-based novel algorithm to calculate individual glomerular filtration rate in cancer patients receiving carboplatinKarin Holweger, Hans-Peter Lipp, Jos H Beijnen, et al.Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 7, 2015
Severe and irreversible myelopathy after concurrent systemic and intrathecal nucleoside analogue treatment for refractory diffuse large B-cell lymphoma: A case report and review of the literatureWinfried H Alsdorf, Michael Schmitz, Aneta Schieferdecker, et al.Annals of Hematology|November 16, 2022
VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experienceSusanne Ghandili, Dzenefa Alihodzic, Christian Wiessner, et al.Pageof 74